Current Liabilities
Accrued Liabilities & Other
Salesforce Accrued Liabilities & Other decreased by 20.2% to $6.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.4%, from $5.8B to $6.58B. Over 5 years (FY 2021 to FY 2026), Accrued Liabilities & Other shows an upward trend with a 13.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2015
Last reportedQ1 2027May 28, 2026
Metric ID:
accrued_liabilities_and_other_currentHistorical Data
21 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.44B | $4.27B | $4.23B | $5.47B | $4.6B | $5.45B | $5.29B | $6.74B | $5.73B | $5.06B | $5.31B | $6.11B | $5.52B | $5.22B | $5.33B | $6.66B | $5.8B | $5.4B | $5.85B | $8.25B | $6.58B |
| QoQ Change | — | +24.3% | -1.0% | +29.3% | -15.9% | +18.3% | -3.0% | +27.6% | -15.0% | -11.8% | +4.9% | +15.1% | -9.7% | -5.4% | +2.1% | +24.9% | -12.8% | -7.0% | +8.4% | +41.1% | -20.2% |
| YoY Change | — | — | — | — | +33.8% | +27.4% | +24.9% | +23.3% | +24.5% | -7.1% | +0.4% | -9.4% | -3.7% | +3.2% | +0.4% | +9.0% | +5.1% | +3.4% | +9.7% | +24.0% | +13.4% |
Range$3.44B – $8.25B
CAGR+13.9%
Avg YoY Growth+10.7%
Median YoY Growth+9.0%
Accrued Liabilities & Other at Other Companies
Frequently Asked Questions
- What is Salesforce's accrued liabilities & other?
- Salesforce (CRM) reported accrued liabilities & other of $6.58B in Q1 2026.
- How has Salesforce's accrued liabilities & other changed year-over-year?
- Salesforce's accrued liabilities & other increased by 13.4% year-over-year, from $5.8B to $6.58B.
- What is the long-term trend for Salesforce's accrued liabilities & other?
- Over 5 years (2021 to 2026), Salesforce's accrued liabilities & other has grown at a 13.6% compound annual growth rate (CAGR), from $4.36B to $8.25B.